Patent · US Active

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy

US12060433B2 · kind B2 · utility

0Cited by

16References

39Claims

0Family size

Assignee

Incyte Corporation · US

Inventors

Horacio G. Nastri · Needham, US
Shaun M. Stewart · Chadds Ford, US
Juan Carlos Almagro · Brookline, US
Jing Zhou · Sichuan, CN
Rebecca A. Buonpane · Gaithersburg, US
Hui-Qin Wang · Cambridge, US
Yingnan Chen · Wilmington, US
Xiaozhao Wang · Readington, US
Peter Carlsen · Claymont, US
Yong Li · Newark, US
Chao Qi · Newark, US
Liangxing Wu · Wilmington, US
Wenqing Yao · Kennett Square, US
Wenyu Zhu · Wilmington, US
Taisheng Huang · Wilmington, US

Key dates

Filing date	Dec 30, 2020
Grant date	Aug 13, 2024
Priority date	—
Expiry date	Oct 21, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.